Roche Forges Ahead With Taspoglutide Despite Other GLP-1 Cancer Signal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche is forging ahead with its glucagon-like peptide-1 analog taspoglutide despite reports of adenomas (benign tumors) in animal studies and the stumbling block Novo Nordisk hit with its competing type 2 diabetes product Victoza (liraglutide) due to a thyroid cancer signal in animals